Infographic: Assessing the benefits and costs of risk-stratified surveillance for patients with metabolic-associated fatty liver disease
About one in three Australians have metabolic-associated fatty liver disease (MAFLD) – a liver disease common in people who are overweight, obese, or have other metabolic conditions.